Heron Therapeutics Inc. (NASDAQ:HRTX) shares dropped 2.1% during trading on Thursday . The stock traded as low as $19.31 and last traded at $19.44, with a volume of 245,176 shares traded. The stock had previously closed at $19.85.

HRTX has been the subject of several research reports. Cantor Fitzgerald restated a “buy” rating and issued a $41.00 price objective on shares of Heron Therapeutics in a report on Wednesday, August 3rd. Jefferies Group restated a “buy” rating and issued a $46.00 price objective on shares of Heron Therapeutics in a report on Wednesday, July 27th. Cowen and Company restated a “buy” rating on shares of Heron Therapeutics in a report on Saturday, July 9th. Leerink Swann reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, June 27th. Finally, Brean Capital reiterated a “buy” rating and issued a $55.00 price target on shares of Heron Therapeutics in a research note on Friday, May 6th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $47.70.

The company’s 50 day moving average is $18.54 and its 200 day moving average is $18.82.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.21. On average, equities analysts forecast that Heron Therapeutics Inc. will post ($4.39) earnings per share for the current fiscal year.

In other news, insider Robert Rosen sold 100,000 shares of the business’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the sale, the insider now directly owns 102,640 shares of the company’s stock, valued at $2,391,512. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A hedge fund recently bought a new stake in Heron Therapeutics stock. Swiss National Bank acquired a new stake in shares of Heron Therapeutics Inc. (NASDAQ:HRTX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 41,200 shares of the biotechnology company’s stock, valued at approximately $1,100,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.